Langues

7 August 2017 - Just Published: article on NLX-112 analgesic activity in mouse

The Neurolixis drug candidate for treatment of dyskinesia (LID) in Parkinson's disease, NLX-112, was tested in a new study of analgesic activity. It exhibited potent analgesic activity in the mouse formalin test, a model of tonic pain, possibly through activation of spinal cord serotonin 5-HT1A receptors. NLX-112 was also active, albeit less potently, in other pain tests suggesting that it may have beneficial properties on chronic pain symptoms in Parkinson's disease, in addition to its potent anti-dyskinetic activity against L-DOPA-induced dyskinesia (LID), as previously described.

Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain

Sałat K, Kołaczkowski M, Furgała A, Rojek A, Śniecikowska J, Varney MA, Newman-Tancredi A
Neuropharmacology. 2017 Jul 24;125:181-188. doi: 10.1016/j.neuropharm.2017.07.022.